Active peptide composition for adjusting emotion and improving side effects of medicine

Abstract

The invention provides an active peptide composition for regulating emotion and improving side effects of drugs, and relates to the technical field of active peptide compositions. The active peptide composition provided by the invention comprises an emotion regulating component and a nerve recovery promoting component, the emotion regulating component comprises theanine, gamma-aminobutyric acid (GABA), a perilla leaf extract, nano curcumin and a black pepper extract, and the components have a synergistic effect to jointly inhibit depression and central nervous system hyperexcitation and regulate emotion; the nerve recovery promoting component comprises N-acetylneuraminic acid, phosphatidylserine, brain peptide VVAVP and a perilla leaf extract, and the components cooperate with one another, so that brain recovery is promoted, anxiety is reduced, and memory is improved; the emotion regulating component and the nerve recovery promoting component cooperate with each other, the dosage of the components is optimized, depression and central nervous hyperexcitation are jointly inhibited, emotion is regulated, brain recovery is promoted, anxiety is reduced, memory is improved, the digestion and absorption effects are good, and burden on intestines and stomach is small.

Description

Technical Field

[0001] This invention relates to the field of active peptide composition technology, and more particularly to an active peptide composition for regulating mood and improving drug side effects. Background Technology

[0002] In modern society, the pace of life is fast, competition is intensifying, and pressure is increasing. When faced with difficulties, setbacks, or illness, anxiety and depression often render people unable to eat or sleep. How to regulate, control, and overcome negative emotions and maintain a positive mindset is a problem that everyone needs to confront.

[0003] The pressures of modern life, stemming from work, family, and daily routines, cause many people to experience emotional tension, leading to problems such as difficulty falling asleep, frequent dreams and awakenings, and poor sleep quality. According to data released by the World Health Organization and the Sleep Medicine Professional Committee of the Chinese Medical Association, approximately 27% of the global population suffers from sleep problems, with over 60% of adults experiencing sleep issues. In my country, the figure is 24.6%, with a staggering 57% of adults experiencing sleep problems. Furthermore, 94.1% of residents feel their sleep is not at a good level. The main causes of insomnia are, in order of frequency, emotional fluctuations, life stress, and work stress. Younger generations are more prone to insomnia due to emotional, stressful, and other personal factors. Data from the "China Sleep Diagnosis and Treatment Status Survey Report" and the "2018 China Internet Users' Sleep White Paper" released by the Chinese Sleep Research Society in 2018 shows that over 60% of severe insomnia sufferers are from the post-90s generation, with a significant proportion also among children and adolescents. Sleep problems have become a health issue affecting all age groups.

[0004] Short-term insomnia can cause a haggard appearance and accelerate aging; in severe cases, it can lead to a series of pathological reactions, such as fatigue, dizziness, memory loss, palpitations, sweating, and mood changes, ultimately disrupting the normal rhythm of excitation and inhibition in the brain and causing neurological functional diseases such as neurasthenia.

[0005] Currently, many drugs or foods used to regulate mood, both domestically and internationally, have poor therapeutic or regulatory effects. Furthermore, long-term use can place a heavy burden on the body's digestion and absorption, leading to conditions such as poor gastrointestinal function or even liver and kidney damage. Summary of the Invention

[0006] In order to improve the efficacy of existing mood-regulating compositions and reduce their side effects, this application provides an active peptide composition for improving the side effects of mood-regulating drugs.

[0007] In a first aspect, this application provides an active peptide composition for regulating mood and improving drug side effects:

[0008] An active peptide composition for regulating mood and improving drug side effects, comprising, by weight, the following components:

[0009] Brain peptide VVAVP 0.5-1.5 parts;

[0010] Theanine 0.1-0.6 parts;

[0011] N-acetylneuraminic acid 0.5-1 part;

[0012] Perilla leaf extract 0.1-1.5 parts;

[0013] Phosphatidylserine 0.5-1 part;

[0014] Oligosaccharide 0.5-1.0 parts;

[0015] Microcapsule 19-35.2 parts;

[0016] The inclusions of the microcapsule comprise gamma-aminobutyric acid, nano-curcumin, black pepper extract, brain peptide VVAVP, and casein hydrolysate.

[0017] The inclusions of the microcapsule comprise gamma-aminobutyric acid, nano-curcumin, black pepper extract, brain peptide VVAVP, and casein hydrolysate.

[0018] The composition comprises a mood-regulating component and a nerve recovery-promoting component;

[0019] In the mood-regulating component, theanine and gamma-aminobutyric acid (GABA) inhibit excessive excitement of the central nervous system and regulate mood; perilla leaf extract reduces oxidative damage to neurons, reduces anxiety, and improves memory; nano-curcumin and black pepper extract are combined to reduce neural inflammation; theanine, gamma-aminobutyric acid, perilla leaf extract, nano-curcumin, and black pepper extract synergistically adjust mood, inhibit excessive excitement of the central nervous system, and regulate mood.

[0020] In the nerve recovery-promoting component, N-acetylneuraminic acid and phosphatidylserine are combined to repair cell membranes; combined with brain peptide VVAVP, which promotes the growth of brain synapses, to accelerate the recovery of nerve function; perilla leaf extract reduces oxidative damage to neurons, reduces anxiety, and improves memory; N-acetylneuraminic acid, phosphatidylserine, brain peptide VVAVP, and perilla leaf extract synergistically promote brain recovery, reduce anxiety, and improve memory.

[0021] The mood-regulating component and the nerve recovery-promoting component synergistically inhibit excessive excitement of the central nervous system, regulate mood, promote brain recovery, reduce anxiety, and improve memory.

[0022] Further, the mass ratio of gamma-aminobutyric acid, nano-curcumin, black pepper extract, brain peptide VVAVP, and casein hydrolysate in the microcapsule is 0.1-0.6:0.3-1.5:0.1-0.7:0.5-1.5:0.5-1.5.

[0023] Further, the microcapsule is a chitosan microcapsule.

[0024] Further, the mass ratio of chitosan to the inclusions in the chitosan microcapsule is 1.24-1.97:1.

[0025] Further, the chitosan microcapsule further comprises a protective agent, and the amount of the protective agent is 5-10% of the mass of the brain peptide VAVP.

[0026] Further, the protective agent is trehalose and / or mannitol.

[0027] In a second aspect, the application provides a preparation method of the active peptide composition for adjusting the side effects of mood-improving drugs.

[0028] Further, the preparation method of the active peptide composition for adjusting the side effects of mood-improving drugs comprises the preparation of the chitosan microcapsule, and the specific preparation process is as follows:

[0029] Raw material dissolution and active ingredient loading:

[0030] After the chitosan is dissolved in an acidic solution, the pH is adjusted to 4-6.5; 0.1-0.4 g / mL GABA solution, 0.1-0.4 g / mL brain peptide PBS solution, and 0.1-0.5 g / mL casein peptide aqueous solution are sequentially added to the chitosan solution;

[0031] Then, 0.1-0.7 g / mL nano-curcumin ethanol solution is slowly added to the system, and ultrasonic treatment is performed to assist dispersion; then, 0.05-0.3 g / mL black pepper extract solution is added under light shielding conditions, and the mixture is stirred at 30-45°C under light shielding;

[0032] Crosslinking and solidification:

[0033] 1% TPP solution is added dropwise, and the mixture is stirred to form a microsphere suspension.

[0034] Further, the amount ratio of chitosan to TPP is 3-6:1.

[0035] Further, the amount ratio of chitosan to TPP is 4-5:1.

[0036] Beneficial effects:

[0037] 1. The active peptide composition provided by the application comprises mood-regulating components and nerve recovery-promoting components.

[0038] The mood-regulating components include theanine, gamma-aminobutyric acid (GABA), perilla leaf extract, nano-curcumin, and black pepper extract, which synergistically inhibit depression and central nervous system hyperexcitability to regulate mood.

[0039] The nerve recovery promoting component includes N-acetylneuraminic acid, phosphatidylserine, brain peptide WWP and perilla leaf extract, and the components are synergistic with each other to promote brain recovery, reduce anxiety and improve memory.

[0040] The mood regulating component and the nerve recovery promoting component are synergistic with each other and preferably used in an amount to jointly inhibit depression and central nervous system overexcitation, regulate mood, promote brain recovery, reduce anxiety, improve memory, have good digestion and absorption effect and have small burden on the stomach and intestines.

[0041] 2. Preferably, the raw materials in the composition that have large stimulation on the stomach and intestines and the peptide that is easily destroyed by gastric acid are prepared into microcapsules for slow release, so that the recovery of the composition on the nerve function and the regulation of the mood are improved, and the stimulation of the composition on the stomach and intestines is reduced and the burden on the body is reduced.

[0042] 3. Further, the amount of chitosan and TPP in the chitosan microcapsule is preferably used so that the microcapsule is appropriately decomposed in the stomach, so that the chitosan and its decomposition products better protect the stomach and intestines; the protective agent in the microcapsule protects the peptide in the microcapsule, improves the activity of the peptide segment and the recovery and regulation of the nerve function.

[0043] 4. In the active peptide composition, phosphatidylserine, casein hydrolysate, oligosaccharide and chitosan are used in combination and in a preferred amount to protect the stomach and intestines, and the drug is released slowly in the form of chitosan microcapsule to promote absorption and reduce the stimulation on the stomach and intestines; N-acetylneuraminic acid, theanine and perilla leaf extract are not released slowly, so that the active peptide composition can regulate the mood more quickly. DETAILED DESCRIPTION

[0044] In order to make the technical scheme of the present application clearer, the present application will be further described in detail below with specific examples.

[0045] Raw material properties: sodium alginate (SA) food grade (viscosity 200-800 mPa·s); chitosan: degree of deacetylation 95%; gamma-aminobutyric acid (GABA) food grade purity ≥98%; nanocurcumin particle size ≤100 nm; black pepper extract: piperine ≥95%; brain peptide WWP: synthesized by Shengong Bioengineering (Shanghai) Co., Ltd., molecular weight ≤1.2 kDa; casein hydrolysate: molecular weight 2 kDa; TPP: analytical pure.

[0046] Preparation Example 1, a chitosan microcapsule, uses raw materials as shown in Table 1, and the preparation process is as follows:

[0047] S1: Preparation of chitosan matrix:

[0048] Chitosan 7 g was added to 200 mL 1% acetic acid solution and stirred (500 rpm) in a 45 °C water bath until completely dissolved. The pH was adjusted to 5.0 with 1 M NaOH and insoluble material was removed by filtration through a 0.45 μm filter.

[0049] S2: Active ingredient stepwise loading:

[0050] 1) Solution preparation:

[0051] A GABA solution was prepared by dissolving GABA 2.0 g in 10 mL deionized water.

[0052] Nanocurcumin 1.5 g was ultrasonically dispersed in 5 mL ethanol at 30 °C to form a nanocurcumin ethanol solution.

[0053] A casein peptide aqueous solution was obtained by dissolving casein hydrolyzed peptide 2.0 g in 10 mL deionized water.

[0054] A brain peptide PBS solution was obtained by dissolving brain peptide VVAVP 1.0 g and mannitol 0.1 g in 5 mL pH 7.4 PBS buffer.

[0055] A black pepper extract solution was obtained by dissolving black pepper extract 0.3 g in 2 mL DMSO under light protection.

[0056] 2) Active ingredient loading:

[0057] The GABA solution, the brain peptide PBS solution, and the casein peptide aqueous solution were added to the chitosan solution in sequence, and stirred at 30 °C for 30 minutes.

[0058] The ultrasonically dispersed nanocurcumin ethanol solution was then slowly added dropwise to the system while ultrasonically treating (200 W*5 min) to assist dispersion.

[0059] The black pepper extract solution was then added under light protection, and stirred at 40 °C for 1 hour under light protection.

[0060] S3: Crosslinking and solidification

[0061] The 1% TPP solution was added dropwise at a controlled rate of 1 mL / min while maintaining the pH at 5.5. Stirring was continued for 2 hours to form a microsphere suspension.

[0062] S4: Post-treatment:

[0063] The microsphere suspension was centrifuged to discard the supernatant. The free TPP was then removed by dialysis against ultrapure water for 48 hours. The microspheres were then pre-frozen at -50 °C for 6 hours and freeze-dried for 24 hours to obtain chitosan microcapsules having a particle size of 1 mm (in other embodiments, the particle size can be any value in the range of 0.5-2.5 mm).

[0064] Preparation Example 2 to Preparation Example 3, a chitosan microcapsule, differs from Preparation Example 1 in that the type and / or amount of the raw material used is different, and specifically as shown in Table 1.

[0065] Table 1, list of raw materials used in the preparation of the chitosan microcapsule in Preparation Example 1 to Preparation Example 3

[0066]

[0067] Preparation Example 4, a chitosan microcapsule, differs from Preparation Example 1 in that the ratio of the amount of chitosan to TPP is 3:1.

[0068] Preparation Example 5, a chitosan microcapsule, differs from Preparation Example 1 in that the ratio of the amount of chitosan to TPP is 6:1.

[0069] Preparation Example 6, a chitosan microcapsule, differs from Preparation Example 1 in that no protective agent is used.

[0070] Preparation Example 7, a chitosan microcapsule, differs from Preparation Example 1 in that β-cyclodextrin is used instead of chitosan; no TPP is used; and the crosslinking agent is glutaraldehyde, with a mass ratio of β-cyclodextrin to glutaraldehyde of 1:0.001.

[0071] Preparation Example 8, a microcapsule, includes the following steps:

[0072] The raw materials used in Preparation Example 1 are prepared according to the type and amount shown in Table 1, and after mixing, are placed in a centrifugal granulator, atomized and sprayed into a 4% aqueous povidone solution, granulated and sized to obtain the core;

[0073] The coating material, cellulose acetate phthalate, is dissolved in 80% ethanol to obtain a sustained-release coating solution.

[0074] The granular core is placed in a multifunctional fluidized bed, and the sustained-release coating solution is uniformly sprayed onto the surface of the core under fluidized conditions, and dried at 60°C to obtain a microcapsule with a particle size of 1 mm;

[0075] The mass ratio of the core to the coating material is 2.1.

[0076] Example 1, an active peptide composition, the preparation raw materials are as shown in Table 2, and the raw materials are mixed according to the proportions to obtain an active peptide composition for adjusting the side effects of mood-improving drugs.

[0077] Example 2 to Example 3, an active peptide composition, differs from Example 1 in that the amount of the raw material is different, and specifically as shown in Table 2.

[0078] Table 2, list of raw materials used in the active peptide composition in Example 1 to Example 3

[0079]

[0080] Examples 4 to 8, an active peptide composition of Example 1, except that the microcapsules are sequentially prepared using the microcapsules of Preparation Examples 4 to 8.

[0081] Comparative Example 1, an active peptide composition of Example 1, except that the active peptide composition does not use brain peptide VVAVP in the microcapsules.

[0082] Comparative Example 2, an active peptide composition of Example 1, except that the active peptide composition does not use perilla leaf extract and oligosaccharides.

[0083] Comparative Example 3, an active peptide composition of Example 1, except that the active peptide composition does not use microcapsules, and the components of the microcapsules are directly used as components of the active peptide composition.

[0084] The specific active peptide composition includes gamma-aminobutyric acid 0.4 g, nano-curcumin 1 g, black pepper extract 0.7 g, brain peptide VVAVP 2 g, casein hydrolysate 1 g, chitosan 15 g, trehalose 0.08 g, theanine 0.3 g, N-acetylneuraminic acid 0.8 g, perilla leaf extract 1 g, oligosaccharides 1 g, and phosphatidylserine 0.8 g.

[0085] Experimental performance:

[0086] Sleep disorders are directly related to mood (including depression and anxiety), and sleep disturbances can significantly affect emotional reactivity and resilience, thereby affecting emotional stability. A sleep disturbance model that simulates the state of human sleep disorders.

[0087] Test animals: SPF male ICR mice (purchased from Shanghai Slake) weighing 18-22 g. These mice were raised in a controlled environment, with room temperature maintained at 22±2°C and humidity at 55%±5%, following a 12h light / dark cycle. They had free access to food and water. A sleep disturbance instrument was used to disturb the sleep of the mice in the experiment, and the inside of the drum was equipped with a food box and a water nozzle to ensure the basic living needs of the animals.

[0088] Animal grouping: After 1 week of adaptive feeding of the mice as described above, the mice were randomly divided into groups (10 mice per group) as control group, model group, and experimental group (corresponding to Examples and Comparative Examples, respectively).

[0089] Animal modeling and intervention method:

[0090] The normal group did not receive sleep disturbance stress and was only given distilled water by gavage; the control group received sleep disturbance stress and was given distilled water by gavage; the experimental group received sleep disturbance and was given 15 mg / kg of the drug by gavage each time, once a day, for 2 consecutive weeks.

[0091] After acclimatizing to the environment for 7 days, all mice, except for the control group, were placed in a rolling drum for 3 consecutive days, 3 hours each day (roller speed 1 r / min). After the acclimatization period, the mice were placed in a sleep disturbance device for a 28-day sleep disturbance model. The active peptide composition was administered from the first day until the end of the experiment. After administration, the mice were placed on cages lined with filter paper, and the number and quality of feces were observed and recorded daily.

[0092] Behavioral evaluation

[0093] After modeling and gavage administration of the composition, behavioral tests such as the elevated cross maze test and tail suspension test were performed to assess the effects of sleep disturbance and the active peptide composition intervention on mouse behavior.

[0094] Elevated cross maze test: The elevated cross maze test can be used to evaluate anxiety behavior in animals. The specific procedure is as follows: Mice are placed in the central area of ​​the maze, facing the open arms, and are allowed to move freely for 6 minutes. The percentage of time spent in the open arms and the percentage of times the mice enter the open arms are counted for each group.

[0095] Tail suspension experiment:

[0096] The tip of the mouse's tail (2 cm from the tip) was taped to a suspension bar (30 cm above the ground). The mouse was then allowed to touch the suspension. Initially, the mouse instinctively struggled violently to escape, but if unable to escape, it became immobile in a state of despair, exhibiting depressive-like behavior. The longer the immobility, the more depressed the mouse became. Movement was monitored using a video tracking system for 6 minutes, and the immobility time for each animal during the test was calculated (immobility was defined as movement without voluntary or escapist intent).

[0097] Sample collection:

[0098] Mice were given medication 30 minutes after the first day of behavioral testing. Serum was incubated at 4°C for 4 hours and then centrifuged.

[0099] The samples were isolated and stored at -80°C for subsequent use to determine serum corticosterone levels. Mice were immediately euthanized by decapitation after blood collection. The entire brain was rapidly dissected on ice, and hippocampal tissue was isolated in pre-chilled PBS. After blotting off surface liquid with filter paper, the tissue was immediately transferred to a -80°C freezer for storage. Sample pretreatment included homogenization of brain tissue using an ultrasonic homogenizer, protein precipitation with internal standard solution and trifluoroacetic acid, and the supernatant was used for neurotransmitter content determination. High-performance liquid chromatography (HPLC) was used to quantify mouse hippocampal serotonin (5-HT).

[0100] Table 3. List of behavioral and defecation evaluation results of mice in the gavage examples, comparative examples, normal groups, and control groups.

[0101]

[0102] Compared with Example 4, the composition of Example 1 has better mood regulation function, which may be due to the higher content of TPP and less decomposition of chitosan in the stomach, resulting in less chitosan and its decomposition products in the gastrointestinal tract, and weakening the gastrointestinal protection function.

[0103] Compared with Example 5, Example 1 has more defecation number and defecation amount, indicating that the composition of Example 1 has better gastrointestinal function, which may be due to the use of chitosan and TPP in a ratio of 6:1 in Example 5, the lower content of TPP, the faster decomposition of the prepared microcapsules in the stomach, the more contained slow-release, the certain irritation to the stomach, the weakening of the protection function of the intestine, and the more loss of activity of the peptide substances, the weakening of the mood regulation function; the composition of Example 1 is more conducive to restoring the balance of neurotransmitters, and has better anti-mood disorder and gastrointestinal protection function.

[0104] Compared with Example 6, Example 1 has stronger mood regulation function, which may be due to the fact that no protective agent is used in Example 6, and after partial decomposition of the chitosan microcapsules in the stomach, more peptide substances lose activity, and the mood regulation function and the gastrointestinal protection function are weakened.

[0105] The compositions of Examples 7 and 8 have more obvious gastrointestinal side effects, and the composition of Example 1 has smaller gastrointestinal side effects, which may be due to the fact that the microcapsule carrier in Example 1 contains chitosan, which is partially decomposed in the stomach and has a protection function on the gastrointestinal tract, indicating that chitosan in the composition synergizes with phosphatidylserine, casein hydrolysate and oligosaccharide, and has a better protection effect on the gastrointestinal tract.

[0106] Comparing the experimental results of Comparative Example 1 and Example 1, it is shown that the use of brain peptide VVAVP in the composition is conducive to restoring the balance of neurotransmitters and resisting mood disorders; part of the brain peptide VVAVP is prepared into microcapsules, and part is directly used as a component of the composition, which is conducive to the absorption of brain peptide VVAVP.

[0107] Compared with Comparative Example 2, the composition of Example 1 has better mood regulation function and smaller gastrointestinal side effects, which may be due to the use of oligosaccharide in the composition, which reduces the irritation of the raw materials directly used as the components of the composition to the gastrointestinal tract; it is shown that perilla leaf extract has a good compatibility and synergistic effect with N-acetylneuraminic acid, theanine, brain peptide VVAVP and other mood regulation components in the composition.

[0108] Compared with Comparative Example 3, the composition of Example 1 has better mood regulation function and less gastrointestinal side effects, indicating that the preparation of microcapsules for slow release of raw materials with greater gastrointestinal irritation and peptides easily destroyed by gastric acid in the composition improves the recovery of neural function and mood regulation of the composition, while reducing the gastrointestinal irritation of the composition and reducing the burden on the body.

[0109] The above examples only express several embodiments of the present application, which are described in more detail and in more detail, but cannot be understood as limiting the scope of the patent of the present application. It should be noted that for ordinary skilled persons in the art, without departing from the concept of the present application, several modifications and improvements can be made, which belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application should be subject to the appended claims.

Claims

1. An active peptide composition for regulating mood and improving drug side effects, characterized in that, Based on parts by weight, it includes the following components: Brain peptide VVAVP 0.5-1.5 parts; Theanine 0.1-0.6 parts; 0.5-1 part of N-acetylneuraminic acid; Perilla leaf extract 0.1-1.5 parts; Phosphatidylserine 0.5-1 part; Oligosaccharides 0.5-1.0 parts; Microcapsules: 19-35.2 parts; The microcapsules contain γ-aminobutyric acid, nano-curcumin, black pepper extract, brain peptide VVAVP, and casein hydrolysate peptides.

2. The active peptide composition for regulating mood and improving drug side effects according to claim 1, characterized in that, The mass ratio of γ-aminobutyric acid, nano-curcumin, black pepper extract, brain peptide VVAVP, and casein hydrolysate in the microcapsules is 0.1-0.6: 0.3-1.5: 0.1-0.7: 0.5-1.5: 0.5-1.

5.

3. The active peptide composition for regulating mood and improving drug side effects according to claim 1, characterized in that, The microcapsules are chitosan microcapsules.

4. The active peptide composition for regulating mood and improving drug side effects according to claim 3, characterized in that, The mass ratio of chitosan to the contents in the chitosan microcapsules is 1.24-1.97:

1.

5. The active peptide composition for regulating mood and improving drug side effects according to claim 3, characterized in that, The chitosan microcapsules include a protective agent, the amount of which is 5-10% of the mass of the brain peptide VVAVP.

6. The active peptide composition for regulating mood and improving drug side effects according to claim 5, characterized in that, The protective agent is trehalose and / or mannitol.

7. A method for preparing an active peptide composition for adjusting mood and improving drug side effects as described in any one of claims 1-6.

8. A method for preparing an active peptide composition for regulating mood and improving drug side effects according to claim 7, characterized in that, The preparation of chitosan microcapsules is included, and the specific preparation process is as follows: Raw material dissolution and active ingredient loading: After dissolving chitosan in an acidic solution, adjust the pH to 4-6.5; then add 0.1-0.4 g / mL γ-aminobutyric acid solution, 0.1-0.4 g / mL brain peptide PBS solution, and 0.1-0.5 g / mL casein peptide aqueous solution to the chitosan solution in sequence. Next, 0.1-0.7 g / mL of nano-curcumin ethanol solution was slowly added dropwise to the system, while sonication was used to aid dispersion; then, 0.05-0.3 g / mL of black pepper extract solution was added under light-protected conditions, and the mixture was stirred and mixed at 30-45°C in the dark. Cross-linking and curing: Add 1% TPP solution dropwise and stir to form a microsphere suspension.

9. A method for preparing an active peptide composition for regulating mood and improving drug side effects according to claim 8, characterized in that, The ratio of chitosan to TPP is 3-6:

1.

10. A method for preparing an active peptide composition for regulating mood and improving drug side effects according to claim 9, characterized in that, The ratio of chitosan to TPP is 4-5:1.

Images